Printer Friendly

AFFINITY BIOTECH APPOINTS BOARD MEMBER TO NEW SEAT

 BOOTHWYN, Pa., Oct. 13 /PRNewswire/ -- Affinity Biotech, Inc. (NASDAQ: AFBI) today announced that it has added Richard L. Sherman to its board of directors, increasing the number of board members to 14. Mr. Sherman has in the past served as Affinity's legal counsel on a variety of commercial transactions.
 "Mr. Sherman's expertise in pharmaceutical transactions has already been of great value to Affinity," said Alan Dickason, president and CEO of the company. "We expect him to play an instrumental role as a member of our board as Affinity expands its pharmaceutical industry outreach."
 Mr. Sherman, 46, is founder of QED Technologies, Malvern, Pa., a technology an business development consulting firm. He is also a principal in CIP Capital, L.P., a venture capital SBIC, and serves as special counsel to the Philadelphia-based law firm of Pepper, Hamilton & Scheetz. He has extensive experience in international and domestic commercial transactions and corporate partnering relationships, with particular expertise in pharmaceuticals, medial devices, biotechnology, and other life-science technologies. He has more than 20 years of experience counseling high technology businesses, venture funds, and multinational life sciences companies in the United States, Europe and Japan.
 Mr. Sherman previously served as deputy general counsel for SmithKline Beckman Corporation. In this role, he was responsible for worldwide legal operations and represented SmithKline Beckman in its major transactions, including joint ventures, venture investments, research and development collaborations, and partnering relationships.
 Mr. Sherman is a member of the investment advisory committee of the Ben Franklin Technology Center, a Pennsylvania state-supported fund which provides seed capital to technology oriented start-up companies. He was a Root-Tilden Scholar at New York University School of Law where he earned a J.D.
 Based in Boothwyn, Affinity Biotech applies proprietary technology to the development of advanced drug delivery systems, new or improved formulations of liquid and chewable drugs, and unique consumer products. Through a recently formed subsidiary, Affinity offers a broad range of product development services to the pharmaceutical and biotechnology industries, including formulation development, analytical services, and product testing.
 -0- 10/13/93
 /CONTACT: Wayne B. Weisman, executive vice president of Affinity Biotech, 215-497-0500, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, 212-696-4455/
 (AFBI)


CO: Affinity Biotech, Inc. ST: Pennsylvania IN: MTC SU: PER

TS-LG -- NY015 -- 1498 10/13/93 08:47 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1993
Words:382
Previous Article:CISTRON PROFITABLE FOR FIFTH STRAIGHT YEAR
Next Article:STARBUCKS COFFEE RINGS IN THE HOLIDAYS WITH A SLEIGH FULL OF REGALI PORTA VIA (GIFTS TO GO)
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters